SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
Rhea-AI Summary
SCIENTURE HOLDINGS (NASDAQ: SCNX) announced management will participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9–10, 2025. Narasimhan Mani, President and co-CEO, will present at 2:00 PM ET on December 9. Shankar Hariharan, Executive Chairman and co-CEO, will join one-on-one investor meetings on December 10. A live webcast of the presentation is available at the conference link and a replay will be posted on the company’s investor site under Events and Presentations. The two-day event features Day 1 webcasts and Day 2 one-on-one investor meetings for pre-qualified investors.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SCNX gained 0.13%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $32K to the company's valuation, bringing the market cap to $25M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SCNX fell 2.9% while momentum-screened peers HKPD and PETS were moving up (13.92% and 4.02%), suggesting stock-specific dynamics rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Strategic partnership | Positive | -2.9% | Collaboration with BlinkRx to expand national access to Arbli™. |
| Dec 02 | Investor conference | Neutral | +0.1% | Announcement of participation in iAccess Alpha investor conference. |
| Nov 13 | Earnings update | Positive | -5.5% | Q3 2025 results highlighting revenue growth and Arbli launch. |
| Nov 04 | Market access news | Positive | +15.3% | Arbli added to major national health plan formularies. |
| Oct 23 | Commercial launch | Positive | +354.9% | Start of commercial sales and first orders for Arbli™. |
Product and market access milestones for Arbli™ have coincided with strong positive moves, while some later positive or strategic updates, including earnings and partnerships, saw negative reactions.
Over the last few months, SCNX transitioned from launching Arbli™ commercial sales on Oct 23, 2025 to expanding access via GPO and payor formularies and reporting Q3 2025 results with early revenue ramp. The stock reacted strongly to the initial Arbli™ launch and formulary additions, while subsequent earnings and a BlinkRx collaboration drew weaker or negative price responses. Today’s conference participation on Dec 9–10, 2025 fits into this broader effort to increase investor visibility around its specialty pharma strategy and commercialization progress.
Regulatory & Risk Context
The company has an active Form S-3 shelf filed on 2025-08-01, with multiple recent 424B5 prospectus supplements indicating it has been used for at-the-market equity offerings. The shelf remains effective through 2028-08-01, providing ongoing flexibility to raise capital via additional share sales.
Market Pulse Summary
This announcement highlights Scienture’s plan to present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9–10, 2025, offering additional exposure to focused small-cap investors. It follows recent commercialization and access milestones for Arbli™ and occurs against a backdrop of active capital markets activity under an S-3 shelf and at-the-market programs. Investors may watch how management frames growth, financing flexibility, and commercialization progress during the presentation and follow-up meetings.
AI-generated analysis. Not financial advice.
COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - 10th, 2025.
Narasimhan Mani, President and co-CEO of Scienture is scheduled to present at 2:00 PM EST on December 9th. Shankar Hariharan, Executive Chairman and co-CEO of Scienture, will join him for one-on-one meetings with investors on December 10th.
The live webcast of Scienture’s presentation will be available at https://www.webcaster5.com/Webcast/Page/3148/53307, and a replay will be accessible afterward. The presentation will also be available on the Company’s website at https://scientureholdings.com/investors/ under the "Events and Presentations" tab.
iAccess Alpha hosts virtual investor conferences featuring high-potential small and micro-cap companies as investment opportunities. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between company management teams and pre-qualified investors on Day 2.
For more information about the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, or to register and schedule a one-on-one meeting with Scienture, please visit the conference website at: https://www.iaccessalpha.com.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
When will SCIENTURE (SCNX) present at the iAccess Alpha Winter Investment Conference 2025?
How can investors watch the SCIENTURE (SCNX) live presentation on December 9, 2025?
Who from SCIENTURE (SCNX) will be available for investor meetings on December 10, 2025?
Where is the SCIENTURE (SCNX) presentation replay posted after the conference?
What is the format of the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025?
How can investors register or schedule a one-on-one meeting with SCIENTURE (SCNX) at the conference?
